Cargando…

Platelet-bound C4d, low C3 and lupus anticoagulant associate with thrombosis in SLE

BACKGROUND: Low C3 and lupus anticoagulant (LAC) are known risk factors for thrombosis in SLE. We evaluated the association between C4d products deposited on platelets (PC4d) and thrombosis in SLE. Antiphosphatidyl serine/prothrombin (PS/PT) complex antibody was also evaluated as an alternative to L...

Descripción completa

Detalles Bibliográficos
Autores principales:	Petri, Michelle A, Conklin, John, O'Malley, Tyler, Dervieux, Thierry
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2019
Materias:	Biomarker Studies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6519690/ https://www.ncbi.nlm.nih.gov/pubmed/31168401 http://dx.doi.org/10.1136/lupus-2019-000318

Ejemplares similares

Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE
por: Merrill, Joan T, et al.
Publicado: (2018)

Erythrocyte complement receptor 1 (ECR1) and erythrocyte-bound C4d (EC4d) in the prediction of poor pregnancy outcomes in systemic lupus erythematosus (SLE)
por: Conklin, John, et al.
Publicado: (2022)

Reduction in erythrocyte-bound complement activation products and titres of anti-C1q antibodies associate with clinical improvement in systemic lupus erythematosus
por: Buyon, Jill, et al.
Publicado: (2016)

Systemic lupus erythematosus and primary fibromyalgia can be distinguished by testing for cell-bound complement activation products
por: Wallace, Daniel J, et al.
Publicado: (2016)

Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements
por: Putterman, Chaim, et al.
Publicado: (2014)

Loss of antiphospholipid antibody positivity post-thrombosis in SLE
por: Khawaja, Muznay, et al.
Publicado: (2020)

Randomised prospective trial to assess the clinical utility of multianalyte assay panel with complement activation products for the diagnosis of SLE
por: Wallace, Daniel J, et al.
Publicado: (2019)

Assessment of the independent associations of IgG, IgM and IgA isotypes of anticardiolipin with thrombosis in SLE
por: Domingues, Vinicius, et al.
Publicado: (2016)

Evaluation of different ways to identify persistent positivity of lupus anticoagulant in systemic lupus erythematosus
por: Petri, Michelle A, et al.
Publicado: (2020)

Cell-bound complement activation products associate with lupus severity in SLE
por: Arriens, Cristina, et al.
Publicado: (2020)

A multianalyte assay panel with cell-bound complement activation products demonstrates clinical utility in systemic lupus erythematosus
por: Alexander, Roberta Vezza, et al.
Publicado: (2021)

BAFF (B cell activating factor) transcript level in peripheral blood of patients with SLE is associated with same-day disease activity as well as global activity over the next year
por: Zollars, Eric, et al.
Publicado: (2015)

Urine proteomic insights from the belimumab in lupus nephritis trial
por: Weeding, Emma, et al.
Publicado: (2022)

Glycosphingolipid-associated β-1,4 galactosyltransferase is elevated in patients with systemic lupus erythematosus
por: Sadras, Vignesh, et al.
Publicado: (2020)

Novel immunoprofiling method for diagnosing SLE and evaluating therapeutic response
por: Lee, Jan-Mou, et al.
Publicado: (2022)

Hydroxychloroquine is associated with lower platelet activity and improved vascular health in systemic lupus erythematosus
por: Cornwell, MacIntosh Grant, et al.
Publicado: (2021)

Cell-bound complement activation products in SLE
por: Ramsey-Goldman, Rosalind, et al.
Publicado: (2017)

Phenotypical changes and clinical significance of CD4(+)/CD8(+) T cells in SLE
por: Yuan, Shiwen, et al.
Publicado: (2022)

Osteopontin is associated with disease severity and antiphospholipid syndrome in well characterised Swedish cases of SLE
por: Wirestam, Lina, et al.
Publicado: (2017)

Comparison of PREDICTS atherosclerosis biomarker changes after initiation of new treatments in patients with SLE
por: McMahon, Maureen, et al.
Publicado: (2019)

Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE
por: Casey, Kerry A, et al.
Publicado: (2018)

Association of the interferon signature metric with serological disease manifestations but not global activity scores in multiple cohorts of patients with SLE
por: Kennedy, William P, et al.
Publicado: (2015)

Performance Characteristics of Different Anti-Double-Stranded DNA Antibody Assays in the Monitoring of Systemic Lupus Erythematosus
por: Mahler, Michael, et al.
Publicado: (2017)

Different indirect immunofluorescence ANA substrate performance in a diagnostic setting of patients with SLE and related disorders: retrospective review and analysis
por: Choi, May Y, et al.
Publicado: (2020)

Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE
por: Anderson, Erik W, et al.
Publicado: (2022)

Effect of anti-P ribosomal and anti-NR2 antibodies on depression and cognitive processes in SLE: an integrated clinical and functional MRI study
por: Chessa, Elisabetta, et al.
Publicado: (2023)

Identification of biomarkers of response to abatacept in patients with SLE using deconvolution of whole blood transcriptomic data from a phase IIb clinical trial
por: Bandyopadhyay, Somnath, et al.
Publicado: (2017)

Anxiety and depression severity in neuropsychiatric SLE are associated with perfusion and functional connectivity changes of the frontolimbic neural circuit: a resting-state f(unctional) MRI study
por: Antypa, Despina, et al.
Publicado: (2021)

Clinical implications of discordance between anti-dsDNA antibodies by multiplex flow immunoassay and Crithidia luciliae assay in a multiethnic racial cohort of patients with SLE
por: Zaminski, Devyn, et al.
Publicado: (2023)

Autoantibodies associated with systemic sclerosis in three autoimmune diseases imprinted by type I interferon gene dysregulation: a comparison across SLE, primary Sjögren’s syndrome and systemic sclerosis
por: Andraos, Rama, et al.
Publicado: (2022)

Predictors of treatment response in a lupus nephritis population: lessons from the Aspreva Lupus Management Study (ALMS) trial
por: McDonald, Stephen, et al.
Publicado: (2022)

Analysis of urinary macrophage migration inhibitory factor in systemic lupus erythematosus
por: Vincent, Fabien B, et al.
Publicado: (2018)

Brain metabolism and autoantibody titres predict functional impairment in systemic lupus erythematosus
por: Mackay, Meggan, et al.
Publicado: (2015)

Blood-based candidate biomarkers of the presence of neuropsychiatric systemic lupus erythematosus in children
por: Brunner, Hermine I, et al.
Publicado: (2014)

Molecular signatures in systemic lupus erythematosus: distinction between disease flare and infection
por: Mackay, Meggan, et al.
Publicado: (2016)

TNF-α and plasma albumin as biomarkers of disease activity in systemic lupus erythematosus
por: Idborg, Helena, et al.
Publicado: (2018)

Type 1 interferon status in systemic lupus erythematosus: a longitudinal analysis
por: Northcott, Melissa, et al.
Publicado: (2022)

Antiphospholipid antibodies are persistently positive at high titers. Additive value of platelet-bound C4d
por: Sciascia, Savino, et al.
Publicado: (2022)

sIL7R concentrations in the serum reflect disease activity in the lupus kidney
por: Lauwerys, B R, et al.
Publicado: (2014)

Inflammatory markers in saliva and urine reflect disease activity in patients with systemic lupus erythematosus
por: Ruacho, Guillermo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9fh4u7jcq44jc9cruoqrm6ighh